Clinical trials are essential for the research and development of treatments for any disease, and mesothelioma is no exception. Participating in a clinical trial offers patients a chance to try new medications and treatments that are not yet available to the general public.
But how do mesothelioma clinical trials work? Pre-clinical research is needed before a clinical trial on humans can commence, this usually consists of many years of research and testing on animals in laboratories and in-vitro testing–which is using human cells in petra dishes. Once this stage is complete, the trial will then move onto testing on mesothelioma patients.
The clinical trial will need to undergo three distinct phases before it’s declared successful or otherwise. Phase I is used to determine how a patient will absorb a drug and how that medicine is then distributed around the body and expelled. Normal, healthy people without mesothelioma are recruited for this initial phase.
Phase II moves onto mesothelioma patients and studies the effects of the drugs or treatments, the dosage required, and measures how effective it is. There are usually only a small number of participants for this stage.
Phase III is needed for the FDA to approve the drug or treatment and requires a much bigger pool of participants to undergo the same process as phase II and to look for any side effects. Read our article to find out more about how clinical trials work.
Mesothelioma Research News is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or another qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.